Yvonne Lau

Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, Dong-Wan Kim, Ranee Mehra et al. · New England Journal of Medicine · 2014 · 1.4K citations · Full text

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models—association with liver and adipose tissue effects

Jing Xu, Shanaka Stanislaus, Narumol Chinookoswong et al. · American Journal of Physiology-Endocrinology and Metabolism · 2009 · 331 citations

Insulin-sensitizing Action, Glucose Tolerance, Fgf21 Actions +22

Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers

Yvonne Lau, Yong Huang, Lynda Frassetto et al. · Clinical Pharmacology & Therapeutics · 2006 · 324 citations

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Byoung Chul Cho, Dong‐Wan Kim, Alessandra Bearz et al. · Journal of Thoracic Oncology · 2017 · 169 citations · Full text

Fasted State, Randomized Phase 1, Medicine +10

Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes

Randy Hecht, Yuesheng Li, Jeonghoon Sun et al. · PLoS ONE · 2012 · 163 citations · Full text

Human Growth, Peptide Science, Biomedical Engineering +24